ATOSAtossa Therapeutics Inc
ATOS
Atossa Therapeutics Inc63,751
Mkt Cap
$41.77MVolume
46,175.0052W High
$19.3552W Low
$3.76PE Ratio
-1.11ATOS Fundamentals
Price
$4.85Prev Close
$5.15Open
$5.1150D MA
$5.29Beta
1.33Avg. Volume
56,140.77EPS (Annual)
-$4.04P/B
1.37Rev/Employee
$0.00$34.80
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer Atossa Therapeutics to Host Virtual KOL Event Featuring...
PR Newswire·3d ago
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...
PR Newswire·9d ago
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...
PR Newswire·13d ago
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug
The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...
PR Newswire·2mo ago
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two...
PR Newswire·2mo ago
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference Atossa Therapeutics Presents Clinical Trial Update Highlighting...
PR Newswire·2mo ago
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...
PR Newswire·3mo ago
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...
PR Newswire·3mo ago
<
1
2
...
>